CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug

• Cadrenal is now planning a randomized, placebo-controlled study alongside standard anticoagulants.
• The company's Phase 2 data showed over a 25% reduction in clotting, though the trial missed its primary endpoint on platelet recovery.
• Cadrenal is also advancing its 12-LOX platform into areas like obesity and diabetes.

Shares of Cadrenal Therapeutics, Inc. (CVKD) saw its retail sentiment peak to a record high late Sunday after the U.S. Food and Drug Administration (FDA) cleared the path for its blood clot drug CAD-1005 to advance into a Phase 3 trial for heparin-induced thrombocytopenia (HIT).

CVKD stock jumped nearly 3% overnight heading into Monday. On Friday, shares fell 2% and extended losses by another 2% in extended trading. 

CVKD Eyes Phase 3 After FDA Feedback

The company said that the guidance came after its End-of-Phase 2 meeting, which was completed in March, covered protocol design, study population, dosing, background therapy, safety database, and the primary endpoint of new or worsening thrombotic events. Based on the feedback, Cadrenal will initiate a randomized, blinded, placebo-controlled Phase 3 trial evaluating CAD-1005 alongside standard anticoagulant therapy.

“Building on our Phase 2 experience with CAD-1005 in HIT and now with FDA guidance for Phase 3, Cadrenal is positioned to pursue a pivotal trial for the first new therapy for HIT in more than two decades,” CEO Quang X. Pham said in a statement.  

In February, Cadrenal reported results from the trial, which showed over a 25% absolute reduction in thrombotic events in patients treated with CAD-1005 on top of standard anticoagulants, compared with placebo. The study did not meet its primary endpoint based on platelet count recovery, which the company said may not be an appropriate indicator for clinical benefit in HIT.

Despite similar platelet recovery rates across both groups, fewer thrombotic events were observed in the CAD-1005 arm, with high event rates continuing in the placebo group. The company had earlier scheduled the End-of-Phase 2 meeting with the FDA in February and subsequently completed it in March, where it clarified a potential registrational pathway and began incorporating regulatory feedback into its Phase 3 protocol.

Cadrenal Targets 2029 NDA with Phase 3 Study

Cadrenal’s Phase 3 study is expected to enroll around 120 patients across up to 50 clinical centers globally. Patients with suspected HIT will be randomized to receive CAD-1005 or placebo while continuing standard anticoagulant therapy and treated for up to 14 days during hospitalization. 

The primary endpoint will assess to see how often patients develop new blood clots, or if existing clots get worse, among those who are confirmed to have HIT, using a lab test called the Serotonin Release Assay, with at least one interim analysis planned. The company said the study is aimed at a potential New Drug Application submission in 2029.

Cadrenal Expands Drug Pipeline

In March, Cadrenal said it was expanding its pipeline of drugs that target the 12-lipoxygenase (12-LOX) pathway after adding more compounds to its portfolio, including some that can be taken orally. However, the company made clear that its focus remains on advancing CAD-1005 for HIT.

However, the company said that early research suggests that blocking the 12-LOX pathway could have potential uses beyond HIT, including in conditions like obesity, type 2 diabetes and other inflammatory diseases. CAD-1005 is currently the only 12-LOX inhibitor currently in clinical-stage development and has received Orphan Drug and Fast Track designations from the FDA, along with orphan drug status from the European Medicines Agency.

How Do Retail Traders Feel About CVKD?

On Stocktwits, retail sentiment for CVKD was ‘extremely bullish’ at a record high of 99/100 amid ‘extremely high’ message volume.

CVKD stock has declined 62% over the past year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: GameStop–eBay Deal Buzz Sparks Retail Backlash, With Some Floating Etsy Instead